Hosted on MSN1mon
Akero Shares Skyrocket as MASH Drug Delivers Game-Changing ResultsShares of Akero Therapeutics (AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, in treating metabolic dysfunction-associated steatohepatitis (MASH).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback